Scarica l'app Stockscreener
56.09
0.30%
-0.17
Dopo l'orario di chiusura:
56.15
0.06
+0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CRSP Giù?
Forum
Previsione
Precedente Chiudi:
$56.26
Aprire:
$54.3
Volume 24 ore:
2.99M
Relative Volume:
0.99
Capitalizzazione di mercato:
$4.84B
Reddito:
$170.10M
Utile/perdita netta:
$-239.59M
Rapporto P/E:
-20.03
EPS:
-2.8
Flusso di cassa netto:
$-191.20M
1 W Prestazione:
-13.39%
1M Prestazione:
+15.63%
6M Prestazione:
+34.86%
1 anno Prestazione:
+2.26%
Intervallo 1D:
$53.70
$56.78
Intervallo di 1 settimana:
$53.70
$65.72
Portata 52W:
$30.04
$71.13
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Nome
Crispr Therapeutics Ag
Settore
Industria
Telefono
(617) 315-4600
Indirizzo
BAARERSTRASSE 14, ZUG
Confronta CRSP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CRSP
Crispr Therapeutics Ag
|
56.09 | 4.86B | 170.10M | -239.59M | -191.20M | -2.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-02-14 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2025-02-12 | Aggiornamento | TD Cowen | Sell → Hold |
| 2025-02-03 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-06 | Reiterato | Needham | Buy |
| 2024-08-02 | Iniziato | Rodman & Renshaw | Buy |
| 2024-06-28 | Ripresa | Guggenheim | Neutral |
| 2024-02-15 | Iniziato | Wolfe Research | Peer Perform |
| 2023-12-11 | Downgrade | TD Cowen | Market Perform → Underperform |
| 2023-10-17 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-09-27 | Iniziato | Mizuho | Buy |
| 2023-08-17 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-04-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Mkt Perform |
| 2023-03-17 | Iniziato | Bryan Garnier | Buy |
| 2023-03-07 | Iniziato | Robert W. Baird | Neutral |
| 2022-10-11 | Iniziato | Morgan Stanley | Underweight |
| 2022-08-09 | Downgrade | Barclays | Overweight → Equal Weight |
| 2022-06-23 | Downgrade | Evercore ISI | Outperform → In-line |
| 2022-06-17 | Iniziato | BMO Capital Markets | Outperform |
| 2022-04-28 | Iniziato | Credit Suisse | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-10-19 | Iniziato | SVB Leerink | Outperform |
| 2021-06-14 | Aggiornamento | Citigroup | Sell → Neutral |
| 2021-04-21 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-03-04 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-12-10 | Reiterato | Chardan Capital Markets | Buy |
| 2020-12-10 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-10 | Reiterato | Needham | Buy |
| 2020-12-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-10-23 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2020-10-05 | Iniziato | BofA Securities | Buy |
| 2020-07-28 | Reiterato | Needham | Buy |
| 2020-07-14 | Iniziato | SunTrust | Buy |
| 2020-06-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-03-05 | Iniziato | Stifel | Hold |
| 2020-02-03 | Downgrade | Evercore ISI | Outperform → In-line |
| 2019-11-19 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-11-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2019-08-01 | Iniziato | Jefferies | Buy |
| 2019-07-26 | Iniziato | Canaccord Genuity | Buy |
| 2019-06-10 | Iniziato | ROTH Capital | Buy |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2019-03-14 | Iniziato | William Blair | Mkt Perform |
| 2019-01-28 | Downgrade | Goldman | Buy → Neutral |
| 2019-01-22 | Downgrade | Citigroup | Neutral → Sell |
Mostra tutto
Crispr Therapeutics Ag Borsa (CRSP) Ultime notizie
Published on: 2025-08-04 01:34:11 - jammulinksnews.com
Privium Fund Management B.V. Purchases 25,100 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
What analysts say about CRISPR Therapeutics AG stockCapitalize on market trends with confidence - jammulinksnews.com
What are CRISPR Therapeutics AG company’s key revenue driversCapitalize on fast-moving stock trends - jammulinksnews.com
Banque Cantonale Vaudoise Purchases Shares of 18,579 CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
What are the latest earnings results for CRISPR Therapeutics AGMaximize gains with data-driven stock picks - jammulinksnews.com
When is CRISPR Therapeutics AG stock expected to show significant growthFree Trading Strategy Suggestions - jammulinksnews.com
What drives CRISPR Therapeutics AG stock priceAchieve consistent double-digit growth - jammulinksnews.com
Published on: 2025-08-03 05:26:58 - jammulinksnews.com
CRISPR Therapeutics (CRSP) Sees 47% Price Increase Over Last Quarter - simplywall.st
CRISPR Therapeutics AG (CRSP) Sees a More Significant Dip Than Broader Market: Some Facts to Know - MSN
Cerity Partners LLC Invests $216,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (NASDAQ:CRSP) Stock Price Down 4.1%Here's What Happened - MarketBeat
Is CRISPR Therapeutics AG a growth stock or a value stockAdvanced Screener Ideas For Every Investor - jammulinksnews.com
Inspire Advisors LLC Invests $459,000 in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics shares rise 1.18% after-hours following Intellia Therapeutics' inducement grants announcement. - AInvest
Q2 EPS Forecast for CRISPR Therapeutics Decreased by Analyst - MarketBeat
Bayforest Capital Ltd Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
How volatile is CRISPR Therapeutics AG stock compared to the marketAI Powered Review For 2025 - jammulinksnews.com
Is CRISPR Therapeutics AG stock overvalued or undervaluedStock Strategy Signals For Smart Trading - jammulinksnews.com
Published on: 2025-07-30 00:12:31 - beatles.ru
Should You Invest in CRISPR Therapeutics (CRSP) Based on Bullish Wall Street Views? - Yahoo Finance
CRISPR Therapeutics to Report Q2 Earnings: What's in the Cards? - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) is ARK Investment Management LLC's 10th Largest Position - MarketBeat
CRISPR Therapeutics AG (CRSP) May Report Negative Earnings: Know the Trend Ahead of Q2 Release - MSN
Nikko Asset Management Americas Inc. Reduces Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics (CRSP) to Release Quarterly Earnings on Monday - MarketBeat
CRISPR Therapeutics AG Breakout Confirmed by Volume MetricsDaily Growth Stock Pick Reports Show Bullish Signals - metal.it
Buy Signal for CRISPR Therapeutics AG Stock Key Technical Indicators to WatchFast Return Equity Trade Forecast Points to Small Caps - metal.it
Envestnet Asset Management Inc. Has $2.32 Million Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Cathie Wood Offloads $16.4M of CRISPR Therapeutics Stock, Adds Absci and Iridium - AInvest
How does CRISPR Therapeutics AG compare to its industry peersGet expert advice on portfolio optimization - jammulinksnews.com
What are the technical indicators suggesting about CRISPR Therapeutics AGConsistent double returns - jammulinksnews.com
The 3 Things That Matter for Vertex Pharmaceuticals Now - The Motley Fool
What are analysts’ price targets for CRISPR Therapeutics AG in the next 12 monthsLightning-fast growth - jammulinksnews.com
What makes CRISPR Therapeutics AG stock price move sharplyDaily Trade Opportunity - Metal.it
CRISPR Therapeutics (NASDAQ:CRSP) Price Target Lowered to $78.00 at Bank of America - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Acquired by Private Advisor Group LLC - MarketBeat
Cathie Wood's Ark Invest Loads Up On Absci, Offloads CRISPR Therapeutics - Benzinga
Jim Cramer Weighed in on These 17 Stocks - Insider Monkey
CRISPR Therapeutics AG (CRSP) Stock Falls Amid Market Uptick: What Investors Need to Know - MSN
CRISPR Therapeutics (NASDAQ:CRSP) Sees Large Volume IncreaseStill a Buy? - MarketBeat
Crispr Therapeutics Ag Azioni (CRSP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.93%
0.15%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):